Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of Venetoclax and Reduced-intensity Conditioning Regimen(RIC) for Allogeneic Stem Cell Transplantation(Allo-HSCT) in Elderly Patients With High-risk Myeloid Malignancies

NCT05583175 is registered in ClinicalTrials.gov with Xianmin Song, MD as lead sponsor.

NCT NCT05583175
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05583175 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of Venetoclax and Reduced-intensity Conditioning Regimen(RIC) for Allogeneic Stem Cell Transplantation(Allo-HSCT) in Elderly Patients With High-risk Myeloid Malignancies
Lead sponsor
Xianmin Song, MD
Phase
Phase 2
Overall status
Unknown status
Start date
November 1, 2022
Completion date
November 1, 2024
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hematopoietic stem cell transplantation, leukemia, myeloid, acute, mds, myeloid malignancy